The Department of Justice announced fraud charges targeting providers who bill Medicare for expensive "skin substitutes," regenerative wound care products that have become a major drain on federal healthcare spending. These biological grafts, used to treat chronic wounds, cost Medicare nearly $15 billion in 2025 alone, making them a prime target for prosecutors investigating healthcare fraud.
Skin substitutes represent one of the fastest-growing categories of Medicare expenses. While legitimate uses exist for severe burns and non-healing wounds, prosecutors allege that many providers bill for the treatments inappropriately, often applying them to routine wounds that respond to standard care. The products, which can cost thousands of dollars per application, have become particularly vulnerable to overutilization schemes where suppliers encourage unnecessary procedures to maximize reimbursement.
This enforcement action represents part of a broader Department of Justice initiative to combat healthcare fraud across the system. Federal prosecutors have identified patterns where wound care clinics and home health agencies submit claims for skin substitutes without proper medical justification. Some providers allegedly apply these expensive products as first-line treatment even when cheaper, evidence-based alternatives would prove equally effective.
The crackdown reflects growing scrutiny of biological products in Medicare billing. Unlike traditional wound dressings that cost hundreds of dollars, skin substitutes can run several thousand dollars per application. When applied to thousands of patients monthly across hundreds of clinics, the costs escalate rapidly, straining the Medicare trust fund.
Wound care specialists note that skin substitutes serve genuine clinical purposes for specific patient populations. The concern among enforcement officials involves cases where providers use these products indiscriminately, billing Medicare for treatments patients may not actually need. Prosecutors are examining billing records, clinical documentation, and patterns of prescribing to identify systematic fraud rather than isolated billing errors.
This enforcement action sends a clear message to wound care providers about Medicare's expectations for appropriate use of expensive biologics. Healthcare providers billing for skin substit